Retrophin takes on Questcor with ACTH analog, files for IPO
This article was originally published in Scrip
Retrophin shares are trading for about twice as much as they did at the beginning of 2013 in the Over the Counter market, so it makes sense for the company focused on therapies for rare and serious diseases to pursue an initial public offering that will move its stock to the Nasdaq index and raise $40m to fund assets recently added to Retrophin's development pipeline.
You may also be interested in...
Company anticipates steady sales of its blockbuster treatment for infantile spasms and other severe conditions for many years, despite agreement to out-license a potential competitor as part of settlement with US trade commission. Settlement resolving investigation into earlier Questcor acquisition also includes $100m fine.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.